What magnitude of intra‑ocular pressure reduction can be expected when using timolol eye drops, Vyzulta (latanoprostene bunod), Zolymbus (netarsudil) and oral acetazolamide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Expected IOP Reduction with Timolol, Vyzulta, Zolymbus, and Acetazolamide

You can expect approximately 25-30% IOP reduction with timolol, 28-33% with Vyzulta (latanoprostene bunod), 10-20% with Zolymbus (netarsudil), and 20-30% with oral acetazolamide, based on the most recent guideline data and FDA-approved labeling.

Individual Medication Effects

Timolol (Beta-Blocker)

  • IOP reduction: 26-27% at trough, 27% at peak 1
  • Absolute reduction of approximately 7 mmHg from baseline 2
  • The Glaucoma Laser Trial demonstrated timolol lowered IOP by 7 mmHg over 2 years 2
  • Meta-analysis data shows relative reductions of -27% at peak and -26% at trough 3

Vyzulta/Latanoprostene Bunod 0.024%

  • IOP reduction: 28-33% depending on time of day
  • Provides superior IOP lowering compared to timolol throughout the 24-hour period 4, 5
  • In the APOLLO study, Vyzulta demonstrated significantly lower mean IOP than timolol 0.5% at all 9 measurement time points over 3 months 5
  • Particularly effective at nocturnal IOP control, reducing IOP 2.3 mmHg more than timolol during sleep 4
  • Works through dual mechanism: prostaglandin analog effect (uveoscleral outflow) plus nitric oxide donation (trabecular meshwork relaxation) 6, 7

Zolymbus/Netarsudil (Rho Kinase Inhibitor)

  • IOP reduction: 10-20% 1
  • This is the least potent of the four medications listed
  • Shown to be noninferior to timolol only in patients with baseline IOP <25 mmHg 8
  • Unique advantage: reduces IOP to similar degree regardless of baseline pressure 8
  • Most common side effect is conjunctival hyperemia 1, 8

Acetazolamide (Oral Carbonic Anhydrase Inhibitor)

  • IOP reduction: 20-30% 1
  • When given as 500 mg orally every 12 hours, produces mean reduction of 48.6% from baseline 9
  • Provides substantial additive effect when combined with timolol

Combination Effects

Timolol + Acetazolamide

When these medications are used together, they demonstrate near-complete additivity 9:

  • Timolol alone: 36% reduction
  • Acetazolamide alone: 48.6% reduction
  • When acetazolamide added to timolol: additional 43.2% reduction
  • When timolol added to acetazolamide: additional 27.6% reduction

This combination is clinically useful for achieving maximal medical IOP lowering before considering surgical intervention.

Clinical Context and Comparative Efficacy

Prostaglandin analogs (including Vyzulta) are the most effective class for IOP reduction 1. Network meta-analysis confirms that bimatoprost, travoprost, and latanoprost are among the most effective agents, with timolol being slightly less effective 10, 3.

Key efficacy hierarchy from guidelines:

  1. Prostaglandin analogs/Vyzulta: 28-33% (most effective, once daily)
  2. Oral acetazolamide: 20-30% (highly effective but systemic side effects limit chronic use)
  3. Timolol: 26-27% (effective, twice daily)
  4. Netarsudil: 10-20% (least effective of these four)

Important Clinical Considerations

Baseline IOP matters significantly: Higher baseline IOP predicts better absolute and relative responses to all medications 11. A 20% reduction target is reasonable based on OHTS criteria, but if baseline IOP is markedly elevated, 20% may be insufficient 1, 12, 1.

Vyzulta provides superior 24-hour coverage: Unlike timolol, which has limited nocturnal efficacy, Vyzulta maintains IOP reduction throughout the sleep period 4. This is clinically relevant since nocturnal IOP spikes contribute to glaucoma progression.

Acetazolamide is not for chronic use: While highly effective (20-30% reduction), systemic side effects including paresthesias, metallic taste, electrolyte imbalances, and risk of kidney stones limit its use to short-term IOP crises or perioperative management 1.

Netarsudil has the mildest effect but offers once-daily dosing and a unique mechanism. It's most appropriate as adjunctive therapy rather than monotherapy in patients requiring substantial IOP lowering 1, 8.

References

Research

Timolol and acetazolamide. A study of concurrent administration.

Archives of ophthalmology (Chicago, Ill. : 1960), 1982

Research

Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2025

Related Questions

What cumulative intra‑ocular pressure reduction can be expected when timolol 0.5% drops twice daily, Vyzulta (latanoprostene bunod) 0.024% once daily, Zolymbus (netarsudil) 0.02% once daily, and oral acetazolamide 250–500 mg every 12 hours are used together in a patient with a baseline intra‑ocular pressure of approximately 24 mmHg?
How does Vyzulta (latanoprostene‑bunod) compare with other glaucoma medications in terms of efficacy and recommended dosing?
What is the mechanism of action of latanoprostene bunod?
What are alternative medications to Roclatan (netarsudil/latanoprost) for lowering intraocular pressure?
Are Vyzulta (latanoprostene bunod) and Zolymbus (netarsudil) in the same drug class?
Should I refer the patient to nephrology immediately and which specific tests should be ordered while awaiting the referral?
What are the differences between the EEG offset and the aperiodic exponent in anesthesiology?
When should entecavir be started in patients with chronic hepatitis B?
Why does a patient with pneumonitis have a dry cough, and why does the cough typically resolve instead of progressing?
What cumulative intra‑ocular pressure reduction can be expected when timolol 0.5% drops twice daily, Vyzulta (latanoprostene bunod) 0.024% once daily, Zolymbus (netarsudil) 0.02% once daily, and oral acetazolamide 250–500 mg every 12 hours are used together in a patient with a baseline intra‑ocular pressure of approximately 24 mmHg?
What is the typical weekly intramuscular dose of testosterone enanthate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.